Specify a stock or a cryptocurrency in the search bar to get a summary
Relmada Therapeutics Inc
RLMDRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. Address: 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Analytics
WallStreet Target Price
12 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RLMD
Dividend Analytics RLMD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RLMD
Stock Valuation RLMD
Financials RLMD
Results | 2019 | Dynamics |